指南与共识免疫规划卫生政策与健康促进

免疫实践咨询委员会关于≥18岁人群使用诺瓦瓦克斯新冠疫苗的临时推荐——美国,2022年7月

Interim Recommendation of the Advisory Committee on Immunization Practices for Use of the Novavax COVID-19 Vaccine in Persons Aged ≥18 years - United States, July 2022.
指南 / 共识 · MMWR Morb Mortal Wkly Rep · 2022-08-05

NVX-CoV2373(诺瓦瓦克斯)新冠疫苗为含Matrix-M佐剂的重组刺突蛋白纳米颗粒疫苗。2022年7月13日FDA发布紧急使用授权,用于≥18岁未接种成人基础免疫,共2剂(每剂含5 μg rS和50 μg Matrix-M佐剂),间隔3周。2022年7月19日ACIP发布≥18岁人群使用该疫苗预防COVID-19的临时推荐。符合方案集效力分析中,针对RT-PCR确诊的有症状COVID-19的疫苗效力为89.6%(95%CI=82.4%-93.8%)。

要点

  • 诺瓦瓦克斯疫苗为重组刺突蛋白纳米颗粒疫苗,含Matrix-M佐剂。
  • FDA紧急使用授权用于≥18岁未接种成人基础免疫,2剂间隔3周。
  • 符合方案集分析疫苗效力89.6%(95%CI=82.4%-93.8%)。

核心结论

  • ACIP发布≥18岁人群使用诺瓦瓦克斯新冠疫苗预防COVID-19的临时推荐,该推荐为临时性,将随新信息更新。

研究设计与样本

  • ACIP基于FDA紧急使用授权及疫苗效力分析数据发布临时推荐,疫苗效力分析采用符合方案集。

主要发现

  • 符合方案集效力分析中,针对RT-PCR确诊的有症状COVID-19的疫苗效力为89.6%(95%CI=82.4%-93.8%)。
  • 疫苗效力评估病例累积期间,SARS-CoV-2优势流行株为Alpha变异株(B.1.1.7)。
  • 报告了与疫苗接种有时序关联的心肌炎或心包炎病例,提示可能存在因果关系。

关键数值与推荐

  • FDA于2022年7月13日发布紧急使用授权,用于≥18岁未接种成人基础免疫,共2剂(每剂含5 μg rS和50 μg Matrix-M佐剂),间隔3周。
  • ACIP于2022年7月19日发布≥18岁人群使用诺瓦瓦克斯疫苗预防COVID-19的临时推荐。

临床怎么用

  • 含佐剂蛋白亚单位诺瓦瓦克斯新冠疫苗为未接种成人提供额外选择,增加公众和疫苗提供者的灵活性。
  • 接种疫苗对预防COVID-19很重要。

局限性

  • ACIP对诺瓦瓦克斯新冠疫苗使用的推荐为临时性,将随更多信息更新。
  • 心肌炎或心包炎病例与疫苗接种存在时序关联,提示可能因果关系。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The NVX-CoV2373 (Novavax) COVID-19 vaccine is a recombinant spike (rS) protein nanoparticle vaccine with Matrix-M adjuvant to protect against infection with SARS-CoV-2, the virus that causes COVID-19. On July 13, 2022, the Food and Drug Administration (FDA) issued Emergency Use Authorization (EUA) for the Novavax vaccine for primary COVID-19 immunization of unvaccinated adults aged ≥18 years, administered as 2 doses (5 μg rS and 50 μg Matrix-M adjuvant in each dose) 3 weeks apart (1). On July 19, 2022, the Advisory Committee on Immunization Practices (ACIP) issued an interim recommendation for use of the Novavax vaccine in persons aged ≥18 years for the prevention of COVID-19.* In the per-protocol† efficacy analysis, vaccine efficacy (VE) against reverse transcription-polymerase chain reaction (RT-PCR)-confirmed symptomatic COVID-19 was 89.6% (95% CI = 82.4%-93.8%). The Alpha variant (B.1.1.7) of SARS-CoV-2 was the predominant circulating variant during the period of case accrual for VE assessments. Cases of myocarditis or pericarditis were reported in temporal association with vaccination, suggesting a possible causal relationship. The ACIP recommendation for the use of the Novavax COVID-19 vaccine is interim and will be updated as additional information becomes available. The adjuvanted, protein subunit-based Novavax COVID-19 vaccine provides an additional option for unvaccinated adults, increasing flexibility for the public and for vaccine providers. Vaccination is important for protection against COVID-19.

来源:MMWR Morb Mortal Wkly Rep,查看原文。版权归原作者所有。

引用

  1. Twentyman E, Wallace M, Roper LE, et al. Interim Recommendation of the Advisory Committee on Immunization Practices for Use of the Novavax COVID-19 Vaccine in Persons Aged ≥18 years - United States, July 2022. MMWR Morb Mortal Wkly Rep. 2022. PMID: 35925807. doi:10.15585/mmwr.mm7131a2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。